Login
$VOR
$18.83 -$0.14 (0.74%) After hours

$VOR 8-K SEC Filings

Filed On Filing
12 Nov 2026 8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities +1 more

This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of November 11, 2026, by and between Vor Biopharma Inc., a Delaware corporation (the “Company”), and RemeGen Co., Ltd. (the “Investor”).

07 Jul 2026 8-K: Departure/Election of Directors or Officers; Compensation

On July 6, 2026, Andrew Levin, M.D., Ph.D., a member of the Board of Directors (the “Board”) of Vor Biopharma Inc. (the “Company”), delivered his notice of resignation, effective immediately. Dr. Levin’s decision to resign was not as a r...

12 Jun 2026 8-K: Submission of Matters to a Vote of Security Holders

(a) Successor to and Continuation of Prior Plan. The Plan was originally adopted by the Board on January 28, 2021, approved by the Company’s stockholders on January 29, 2021 and became effective as of the Original Effective Date. The Pla...

08 Jun 2026 8-K: Regulation FD Disclosure

First and only approved BAFF/APRIL-targeting therapy for IgA nephropathy (IgAN)

27 Mar 2026 8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities +1 more

This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of March 26, 2026, by and among Vor Biopharma Inc., a Delaware corporation (the “Company”), and each of the purchasers listed on Exhibit A attached to this Agreement (each...

12 Jan 2026 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

Global Science. One Purpose. 44th Annual J.P. Morgan Healthcare Conference January 2026

02 Jan 2026 8-K: Departure/Election of Directors or Officers; Compensation

As we have agreed, you will separate from employment with VOR Biopharma Inc. (“VOR” or “Company”) effective December 31, 2025 (your "Separation Date"). This Separation Agreement contains our agreement regarding the finalization of your w...

18 Dec 2025 8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities +2 more

This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of December 15, 2025, by and among Vor Biopharma Inc., a Delaware corporation (the “Company”), and each of the purchasers listed on Exhibit A attached to this Agreement (e...

09 Dec 2025 8-K: Departure/Election of Directors or Officers; Compensation

On December 5, 2025 (the “Effective Date”), the board of directors (the “Board”) of Vor Biopharma Inc. (the “Company”) approved a stock option repricing whereby the exercise price of certain outstanding options to purchase shares of the ...

12 Nov 2025 8-K: Other Events

As representatives (the “Representatives”) of the several Underwriters

03 Nov 2025 8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure

BOSTON, Mass., November 3, 2025 (GLOBE NEWSWIRE) — Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced the appointment of Jeremy Sokolove, M.D., as Chief Medica...

28 Oct 2025 8-K: Regulation FD Disclosure

Global Science. One Purpose. 48-week Phase 3 Clinical Trial Data from China for Telitacicept in Primary Sjögren’s Disease October 28, 2025

17 Sep 2025 8-K: Material Modification to Rights of Security Holders; Other Events

(Pursuant to Section 242 of the General Corporation Law of the State of Delaware)

02 Sep 2025 8-K: Regulation FD Disclosure

Global Science. One Purpose. Corporate Presentation September 2025 Exhibit 99.1

27 Aug 2025 8-K: Departure/Election of Directors or Officers; Compensation

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

27 Aug 2025 8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders +1 more

(a) Successor to and Continuation of Prior Plan. The Plan was originally adopted by the Board on January 28, 2021, approved by the Company’s stockholders on January 29, 2021 and became effective as of the Original Effective Date. The Pla...

22 Jul 2025 8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure

This EMPLOYMENT AGREEMENT (the “Agreement”) is entered into on July 17, 2025 by and between Qing Zuraw (the “Executive”) and Vor Biopharma Inc. (the “Company”).

10 Jul 2025 8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure

This EMPLOYMENT AGREEMENT (the “Agreement”) is entered into on July 9, 2025 by and between Sandy Mahatme (the “Executive”) and Vor Biopharma Inc. (the “Company”).

26 Jun 2025 8-K: Entry into a Material Definitive Agreement; Termination of a Material Definitive Agreement +3 more

This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of June 25, 2025, by and among Vor Biopharma Inc., a Delaware corporation (the “Company”), and each of the purchasers listed on Exhibit A attached to this Agreement (each,...

23 May 2025 8-K: Amendments to Articles/Bylaws; Change in Fiscal Year; Submission of Matters to a Vote of Security Holders

(Pursuant to Section 242 of the General Corporation Law of the State of Delaware)

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support